By Brad Sorensen, CFA
NASDAQ:ENSC
READ THE FULL ENSC RESEARCH REPORT
Zacks Small Cap Research — Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain relief, while greatly limiting the potential for abuse and overdoses that have plagued the American public.
The company announced that it has enrolled the first patient in the pivotal Phase 3 clinical trial of PF614—the company’s lead product candidate. As a reminder to investors new to the ENSC story, which is one we’re very excited about, the company is developing a next-generation opioid therapy that combines effective analgesia with built-in protection against both abuse and overdose—a rare and compelling value proposition in our view. PF61 leverages a proprietary technology called TAAP (“Trypsin-Activated Abuse Protection”), which renders oxycodone inactive until it reaches the small intestine, significantly reducing its potential for misuse. This is not just a reformulation; it's a fundamental rethinking of how opioids can be delivered with safety in mind. The commencement of a Phase 3 trial is a major milestone on the way to potential commercialization and redefining pain care.
But Ensysce isn’t stopping there: building on PF614, they have created PF614-MPAR, a combination therapy that adds MPAR (“Multi-Pill Abuse Resistance”) technology. This innovation is designed to “switch off” further opioid release when more than the prescribed dose is taken, effectively activating an overdose protection mechanism. It’s a breakthrough in concept—and importantly, the U.S. Food and Drug Administration has recognized its potential, granting Breakthrough Therapy designation.
Beyond pain management, Ensysce is expanding its impact into the treatment of opioid use disorder (OUD). Their lead OUD candidate, PF9001, combines the TAAP and MPAR platforms to potentially offer a safer methadone alternative—with oral delivery, reduced cardiovascular risk, and built-in overdose protection. They recently secured a U.S. patent for PF9001, adding strength to their intellectual property portfolio.
Strategically, Ensysce’s management is executing with discipline. Their manufacturing partnerships for PF614 and PF614-MPAR are already in place, positioning the company for efficient scale-up once regulatory approvals move forward. Their collaborative relationship with the FDA, especially around the overdose protection labeling and streamlined regulatory path, underscores not only scientific innovation but also regulatory savvy and further underscores the positive path management is pursuing.
We have written for some time how important the work ENSC is doing is, and continue to believe that. We also believe that investors who invest in such important work have the potential to be rewarded quite well as these solutions to a problem plaguing thousands of families come to fruition. We encourage investors to take a look at ENSC and consider the stock before the anticipated positive testing results from this current trial begin to come in.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.